| Literature DB >> 31101765 |
Bruna Rodrigues Muys1,2,3,4,5, Josane F Sousa1,2,3,6, Jessica Rodrigues Plaça1,2,3, Luíza Ferreira de Araújo1,2,3,7, Aishe A Sarshad4, Dimitrios G Anastasakis4, Xiantao Wang4, Xiao Ling Li5, Greice Andreotti de Molfetta1,2,3, Anelisa Ramão1,2, Ashish Lal5, Daniel Onofre Vidal8, Markus Hafner9, Wilson A Silva10,2,3.
Abstract
Dysregulation of miRNA expression is associated with multiple diseases, including cancers, in which small RNAs can have either oncogenic or tumor suppressive functions. Here we investigated the potential tumor suppressive function of miR-450a, one of the most significantly downregulated miRNAs in ovarian cancer. RNA-seq analysis of the ovarian cancer cell line A2780 revealed that overexpression of miR-450a suppressed multiple genes involved in the epithelial-to-mesenchymal transition (EMT). Overexpression of miR-450a reduced tumor migration and invasion and increased anoikis in A2780 and SKOV-3 cell lines and reduced tumor growth in an ovarian tumor xenographic model. Combined AGO-PAR-CLIP and RNA-seq analysis identified a panel of potential miR-450a targets, of which many, including TIMMDC1, MT-ND2, ACO2, and ATP5B, regulate energetic metabolism. Following glutamine withdrawal, miR-450a overexpression decreased mitochondrial membrane potential but increased glucose uptake and viability, characteristics of less invasive ovarian cancer cell lines. In summary, we propose that miR-450a acts as a tumor suppressor in ovarian cancer cells by modulating targets associated with glutaminolysis, which leads to decreased production of lipids, amino acids, and nucleic acids, as well as inhibition of signaling pathways associated with EMT. SIGNIFICANCE: miR-450a limits the metastatic potential of ovarian cancer cells by targeting a set of mitochondrial mRNAs to reduce glycolysis and glutaminolysis.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/79/13/3294/F1.large.jpg. ©2019 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31101765 PMCID: PMC6606360 DOI: 10.1158/0008-5472.CAN-19-0490
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701